Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

被引:1469
作者
Adler, AI [1 ]
Stratton, IM
Neil, HAW
Yudkin, JS
Matthews, DR
Cull, CA
Wright, AD
Turner, RC
Holman, RR
机构
[1] Univ Oxford, Radcliffe Infirm, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trial Unit, Oxford OX2 6HE, England
[2] Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford OX3 7LF, England
[3] UCL, Sch Med, Whittington Hosp, London N19 3UA, England
[4] Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England
[5] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Res Labs, Oxford OX2 6HE, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2000年 / 321卷 / 7258期
关键词
D O I
10.1136/bmj.321.7258.412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients dth type 2 diabetes. Design Prospective observational study. Setting 23 hospital based clinics in England, Scotland and Northern Ireland Participants 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk, Outcome measures Primary predefined aggregate clinical outcomes: any complications or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, lower extremity amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photocoagulation). Single end points: non-fatal heart failure and cataract extraction Risk reduction associated with a 10 mm Hg decrease in updated mean systolic blood pressure adjusted for specific confounders Results The incidence of clinical complications was significantly associated with systolic blood pressure, except for cataract extraction. Each 10 mm Hg decrease in updated mean systolic blood pressure was associated with reductions in risk of 12% for any complication related to diabetes (95%, confidence interval 10% to 14%, P < 0.0001), 15% for deaths related to diabetes (12% to 18%, P< 0.0001), 11% for myocardial infarction (7% to 14%, P< 0.0001), and 13% for microvascular complications (10% to 16%, P< 0.0001). No threshold of risk was observed for any end point. Conclusions In patients with type 2 diabetes the risk of diabetic complications was strongly associated with raised blood pressure. Any reduction in blood pressure is likely to reduce the risk of complications, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 56 条
  • [1] [Anonymous], 1994, Diabet Med, V11, P773
  • [2] [Anonymous], 1995, Diabetes, V44, P1249
  • [3] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
  • [4] DIABETES-MELLITUS - AN INDEPENDENT RISK FACTOR FOR STROKE
    BARRETTCONNOR, E
    KHAW, KT
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 128 (01) : 116 - 123
  • [5] WHY IS DIABETES-MELLITUS A STRONGER RISK FACTOR FOR FATAL ISCHEMIC-HEART-DISEASE IN WOMEN THAN IN MEN - THE RANCHO-BERNARDO STUDY
    BARRETTCONNOR, EL
    COHN, BA
    WINGARD, DL
    EDELSTEIN, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05): : 627 - 631
  • [6] Evaluation of a self-administered sensory testing tool to identify patients at risk of diabetes-related foot problems
    Birke, JA
    Rolfsen, RJ
    [J]. DIABETES CARE, 1998, 21 (01) : 23 - 25
  • [7] Evidence-based medicine and ACE inhibition
    Borghi, C
    Ambrosioni, E
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 : S24 - S35
  • [8] Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus
    Bruno, G
    Merletti, F
    Boffetta, P
    Cavallo-Perin, P
    Bargero, G
    Gallone, G
    Pagano, G
    [J]. DIABETOLOGIA, 1999, 42 (03) : 297 - 301
  • [9] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [10] COWIE CC, 1995, DIABETES AM